Gilead Sciences

Together we deliver life-saving therapies to patients in need. With the commitment and drive you bring to the workplace every day, you will be part of a team that is changing the world and helping millions of people live healthier, more fulfilling lives. Our worldwide staff of more than 7,000 people is a close community where you can see the tangible results of your contributions, where every individual matters, and everyone has a chance to enhance their skills through ongoing development. Our scientific focus has resulted in 19 marketed products that are benefitting hundreds of thousands of people, a pipeline of late-stage drug candidates and unmatched patient access programs to ensure medications are available to those who could otherwise not afford them.

Today, Gilead's research and development effort is the largest it has ever been and includes approximately 200 clinical studies evaluating compounds with the potential to become the next generation of innovative therapies for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. The commercial success of Gilead's portfolio of 19 products has provided the company with the resources to support the development of new therapeutic advancements. Working at Gilead provides you with plenty of opportunities for career advancement in a growing and fast-paced environment while working with highly-respected teams. We would like to invite you to be a part of the following Gilead organizations that have helped millions of people around the world live healthier and more fulfilling lives.

Company Growth (employees)
Type
Public
HQ
Foster City, US
Founded
1987
Size (employees)
8,000 (est)
Website
gilead.com
Gilead Sciences was founded in 1987 and is headquartered in Foster City, US

Key People at Gilead Sciences

John Milligan

John Milligan

CEO
Kevin Young

Kevin Young

COO

Gilead Sciences Office Locations

Gilead Sciences has offices in Foster City, Fremont, Oceanside, San Dimas and in 12 other locations
Foster City, US (HQ)
333 Lakeside Dr
Seattle, US
199 E Blaine St
Branford, US
36 E Industrial Rd
San Dimas, US
650 Cliffside Dr
Oceanside, US
4049 Avenida De La Plata
Fremont, US
7601 Dumbarton Cir

Gilead Sciences Metrics

Gilead Sciences Financial Metrics

Revenue (2016)

$30.4 b

Revenue growth (2015-16), %

(7%)

Gross profit

$26.1 b

Gross profit margin (2016), %

86%

Net income (2016)

$13.5 b

Market capitalization (21-Mar-2017)

$89.9 b

Closing share price (21-Mar-2017)

$68.7

Cash (31-Dec-2016)

$8.2 b
Gilead Sciences's current market capitalization is $89.9 b.
Gilead Sciences's revenue was reported to be $30.4 b in FY, 2016 which is a 6.9% decrease from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

$11.2 b$24.9 b$32.6 b$30.4 b

Revenue growth, %

122%31%(7%)

Cost of goods sold

$2.9 b$3.8 b$4 b$4.3 b

Gross profit

$8.3 b$21.1 b$28.6 b$26.1 b

Gross profit Margin, %

74%85%88%86%

Operating expense total

$6.7 b$9.6 b$10.4 b$12.8 b

EBIT

$4.5 b$15.3 b$22.2 b$17.6 b

EBIT margin, %

40%61%68%58%

Interest expense

$306.9 m$412 m$688 m$964 m

Pre tax profit

$4.2 b$14.9 b$21.7 b$17.1 b

Income tax expense

$1.2 b$2.8 b$3.6 b$3.6 b

Net Income

$3.1 b$12.1 b$18.1 b$13.5 b
FY, 2013FY, 2014FY, 2015FY, 2016

Cash

$2.1 b$10 b$12.9 b$8.2 b

Inventories

$2.1 b$1.4 b$2 b$1.6 b

Current Assets

$7.3 b$17.7 b$24.8 b$20.4 b

PP&E

$1.2 b$1.7 b$2.3 b$2.9 b

Goodwill

$1.2 b$1.2 b$1.2 b$1.2 b

Total Assets

$22.5 b$34.7 b$51.8 b$57 b

Accounts Payable

$1.3 b$955 m$1.2 b$1.2 b

Total Debt

Current Liabilities

$6.3 b$5.8 b$9.9 b$9.2 b

Additional Paid-in Capital

$5.4 b$2.4 b$444 m$454 m

Retained Earnings

$6.1 b$12.7 b$18 b$18.2 b

Total Equity

$19.1 b$19.4 b

Financial Leverage

2.7 x2.9 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

$3.1 b$12.1 b$18.1 b$13.5 b

Accounts Receivable

($315.3 m)($2.6 b)($1.4 b)$1.2 b

Inventories

($343.1 m)$143 m($855 m)($488 m)

Accounts Payable

($97.7 m)($289 m)$226 m$47 m

Cash From Operating Activities

$3.1 b$12.8 b$20.3 b$16.7 b

Capital Expenditures

($190.8 m)($557 m)($747 m)($748 m)

Cash From Investing Activities

($254.4 m)($1.8 b)($12.5 b)($12 b)

Interest Paid

$238.3 m$330 m$529 m$885 m

Income Taxes Paid

$1.1 b$2.1 b$3.1 b$2.4 b

Free Cash Flow

$3.3 b$13.4 b$21.1 b$17.4 b

Gilead Sciences Operating Metrics

Y, 2015Y, 2016

Drugs Approved by FDA

1A

Ongoing Phase III Programs

10B

Gilead Sciences Market Value History

Gilead Sciences Median Salaries

Source: 349 public H-1B filings from Gilead Sciences

Gilead Sciences Online Presence

Gilead Sciences News

Gilead Sciences Company Life

You may also be interested in